Other substances

Eculizumab

An anti-C5 monoclonal antibody.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Eculizumab is a monoclonal humanized antibody against the C5 complement protein. It has been approved for treatment of certain autoimmune diseases (DrugBank).

Eculizumab on Wikipedia

Marketed as

SOLIRIS

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 Critical severity Case series Antibody	Patients	3.37	Some critically ill COVID-19 patients might benefit from eculizumab treatment. Sample size: 3.	Aug/06/2020
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study Severe severity Antibody Cohort study	Patients		Significantly increased survival at day 15 and 28 compared to control. Improvement in oxygenation and various biochemical markers of tissue hypoxia and inflammation observed, as well. Sample size: 35 + 45 control. Dosage: 900 mg IV on days 1, 8, 15, and 22.	Nov/04/2020

AI-suggested references

Link	Publication date
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.	Jun/04/2020
Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)-A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome.	Dec/03/2021
Complement Blockade with Eculizumab for Treatment of Severe Coronavirus Disease 2019 in Pregnancy: A Case Series.	May/12/2022
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab	Apr/02/2022
Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19	Feb/04/2021
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study	Dec/20/2021
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab	Apr/29/2022
Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab.	Aug/19/2021
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study	Jun/05/2020
A synthetic protein as efficient multitarget regulator against complement over-activation	Apr/03/2020
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.	Sep/19/2020
Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome.	Sep/27/2020
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19	Feb/28/2022
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs	Mar/23/2022
COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy	Mar/01/2022
Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders	Sep/12/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04802083	COVID-19 Soliris Expanded Access Protocol	No longer available		Jan/01/1970	Jan/01/1970
Alternative id - ECU-COV-402 Interventions - Biological: Eculizumab Study type - Expanded Access:Intermediate-size Population Study results - No Results Available Locations - Study designs - Enrollment - Age - 18 Years and older (Adult, Older Adult) Outcome measures -
NCT04288713	Eculizumab (Soliris) in Covid-19 Infected Patients	Available		Jan/01/1970	Jan/01/1970
Alternative id - COVID19 Interventions - Drug: Eculizumab Study type - Expanded Access:Individual Patients\|Treatment IND/Protocol Study results - No Results Available Locations - Study designs - Enrollment - Age - 18 Years and older (Adult, Older Adult) Outcome measures -
NCT04346797	CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort	Recruiting	Phase 2	Apr/16/2020	Dec/31/2020
Alternative id - APHP200375-4 Interventions - Drug: Eculizumab Study type - Interventional Study results - No Results Available Locations - Saint Louis, Paris, Ile De France, France\|Réanimation médicale, Paris, France\|saint Louis, Paris, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 120 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Survival without needs of intubation at day 14\|Change in organ failure at day 3\|Intubation free survival at day 14\|WHO progression scale at days 4, 7 and 14\|Survival at 14, 28 and 90 days\|Time to discharge\|Time to oxygen supply independency\|Time to negative viral excretion\|Incidence of secondary infections\|Vasopressor-free survival\|Ventilator-free survival\|28-day ventilator-free days\|Incidence of dialysis\|PaO2/FiO2 ratio\|Rate of respiratory acidosis at day 4\|Time to ICU discharge
NCT04355494	SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19	No longer available		Jan/01/1970	Jan/01/1970
Alternative id - ECU-COV-401 Interventions - Biological: eculizumab Study type - Expanded Access:Intermediate-size Population Study results - No Results Available Locations - Cedars-Sinai Medical Center, Los Angeles, California, United States\|Boston Medical Center, Boston, Massachusetts, United States\|Newton-Wellesley Hospital, Newton, Massachusetts, United States\|Mayo Clinic, Rochester, Minnesota, United States\|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States\|Icahn School of Medicine at Mount Sinai, New York, New York, United States\|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States\|Hôpital Henri Mondor, Creteil, France\|Hôpital Garches Raymond Poincaré, Garches, France\|Hôpital de Bicêtre, Le Kremlin Bicêtre, France\|Hôpital Saint Louis, Paris, France\|Hôpital Paul Brousse, Villejuif, France Study designs - Enrollment - Age - 18 Years and older (Adult, Older Adult) Outcome measures -

Export (.csv)